Neoadjuvant Niraparib Fails to Produce Substantial Pathologic Responses After Radical Prostatectomy in DDR-Deficient Prostate Cancer
Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab Displays Efficacy in Advanced Urothelial Carcinoma
TAR-200 Produces Unprecedented CR Rates in BCG-Unresponsive, High-Risk NMIBC
Cretostimogene Grenadenorepvec Produces Durable CRs in High-Risk BCG-Unresponsive NMIBC